Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party

In English

Författare

  • Thomas Daikeler
  • Myriam Labopin
  • Massimo Di Gioia
  • Mario Abinun
  • Tobias Alexander
  • Irene Miniati
  • Francesca Gualandi
  • Athanasios Fassas
  • Thierry Martin
  • Carl Philipp Schwarze
  • Nico Wulffraat
  • Maya Buch
  • Antonia Sampol
  • Enric Carreras
  • Benedicte Dubois
  • Bernd Gruhn
  • Tayfun Guengoer
  • David Pohlreich
  • Annemie Schuerwegh
  • Emilian Snarski
  • John Snowden
  • Paul Veys
  • Anders Fasth
  • Stig Lenhoff
  • Chiara Messina
  • Jan Voswinkel
  • Manuela Badoglio
  • Joerg Henes
  • David Launay
  • Alan Tyndall
  • Eliane Gluckman
  • Dominique Farge
Visa allt

Summary, in English

To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemo- philia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2), thyroiditis (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), Graves disease (n = 2), myasthenia gravis (n = 1), rheumatoid arthritis (n = 2), sarcoidosis (n = 2), vasculitis (n = 1), psoriasis (n = 1), and psoriatic arthritis (n = 1). After autologous HSCT for primary AD, the cumulative incidence of secondary AD was 9.8% +/- 2% at 5 years. Lupus erythematosus as primary AD, and antithymocyte globulin use plus CD34(+) graft selection were important risk factors for secondary AD by multivariate analysis. With a median follow-up of 6.2 (0.54-11) years after autologous HSCT, 26 of 29 patients with secondary AD were alive, 2 died during their secondary AD (antiphospholipid syndrome, hemophilia), and 1 death was HSCT-related. This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT. (Blood. 2011;118(6):1693-1698)

Publiceringsår

2011

Språk

Engelska

Sidor

1693-1698

Publikation/Tidskrift/Serie

Blood

Volym

118

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

American Society of Hematology

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1528-0020